ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NVCN Neovasc Inc

30.03
0.00 (0.00%)
16 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neovasc Inc NASDAQ:NVCN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 30.03 27.70 30.00 0 01:00:00

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

03/05/2019 12:30pm

PR Newswire (Canada)


Neovasc (NASDAQ:NVCN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Neovasc Charts.

Conference Call Scheduled for 4:30 pm Eastern Time on May 9th 

NASDAQ, TSX: NVCN

VANCOUVER, May 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2019 and host a conference call and webcast at 4:30 pm Eastern Time on Thursday, May 9, 2019.

 

Conference Call & Webcast
Thursday, May 9th @ 4:30 pm Eastern Time

Domestic:

877-407-9208

International:

201-493-6784

Passcode:

13689510

Webcast:

http://public.viavid.com/index.php?id=133943  

 

A replay of the event will be available via webcast through August 9st on the Company's website, www.neovasc.com, or at http://public.viavid.com/index.php?id=133943.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/neovasc-to-announce-first-quarter-2019-financial-results-on-thursday-may-9th-300843366.html

SOURCE Neovasc Inc.

Copyright 2019 Canada NewsWire

1 Year Neovasc Chart

1 Year Neovasc Chart

1 Month Neovasc Chart

1 Month Neovasc Chart

Your Recent History

Delayed Upgrade Clock